The key to Infection Prevention & Control and Antimicrobial Stewardship is better identification of actual infectious agents.
Sterisis, AMS' most comprehensive program, uses quarterly non-invasive rapid-result PCR testing for 37 distinct respiratory pathogens (including COVID-19) and live remote monitoring of resident EHRs in real time to maintain control of the spread of infectious diseases and combat antibiotic resistance. Our Infection Preventionists work hand-in-hand with nursing facility clinicians to ease their IPC burden and promote better resident outcomes.
AMS Infection Preventionist assigned to your facility
24/7 remote live monitoring of resident EHRs
Infectious Disease Outbreak Alerts
Quarterly non-invasive infectious disease testing of residents resulted through Arkstone Medical’s test assessment analytics
Mentorship and educational services for clinical leadership
Access to AMS Medical Directors
Quarterly non-invasive respiratory testing for 37 distinct pathogens - including COVID-19
As-needed testing for respiratory, GI, UTI, STD issues + COVID-19
Testing results complete in 48-hours
Labs recommended by AMS conduct Polymerase Chain Reaction (PCR) molecular testing that is 99.9% accurate
Treatment recommendations based on test results and infectious disease analytics
Early detection of potential infectious disease outbreaks
Interventional Analytics provide confidence in infection risk reduction
Meets CMS antimicrobial stewardship guidelines
Reduces unnecessary antibiotics
Integrates into your QAPI program
Meets CDC's definition of Comprehensive Surveillance
Improved patient care
AMS has been supporting nursing facilities' IPC programs and reducing antibiotic resistance since early-2018. For more on the history of Sterisis or additional information about any element of our programs, research, cost, IPC or Antimicrobial Stewardship requirements, advice from colleagues, and more, please visit our Resource Center.